← Leaderboards
Sunil Sharma
University Of Utah
$2,103,455
Attributed
$4,693,894
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,693,894 · 2
By mechanism
R44$3,457,194 · 1
R01$1,236,700 · 1
Top collaborators
- Stephen L Lessnick4 shared
- Mohan Rao Kaadige3 shared
- Monil Shah1 shared
Most similar at University Of Utah
Same institution · by research overlap
- Gurkan Mollaoglu$439,082
- William Weihao Tang$252,288
- Cindy Beatriz Jennifer Barba$156,790
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCellsProteinsGene ExpressionBaseMediatingPhenotypeTranscriptome SequencingGenesGene RepressionGene TargetingChimeric ProteinsChildEpigenetic ProcessDeacetylaseDemethylationGene Expression ProfileBoneComplexCell LineCancerousGene ActivationEventBiological Models
Grant awards (7)
A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab$1,460,952
R44 · FY2025 · CA
Development of a potent and selective oral ENPP1 inhibitor for oncology$836,231
R44 · FY2023 · CA
Development of a potent and selective oral ENPP1 inhibitor for oncology$1,160,011
R44 · FY2022 · CA
(PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcoma$309,175
R01 · FY2017 · CA
(PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcoma$309,175
R01 · FY2016 · CA
(PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcoma$309,175
R01 · FY2015 · CA
(PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcoma$309,175
R01 · FY2014 · CA